Baudax Bio reports positive outcome of interim analysis of phase II randomized trial for BX1000 in patients undergoing elective surgery
Baudax Bio, Inc., a pharmaceutical company focused on innovative products for hospital and related settings, announced the successful outcome of its first interim analysis in a phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!